BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 549 filers reported holding BIO-TECHNE CORP in Q1 2022. The put-call ratio across all filers is 0.27 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $9,751,640 | +150.7% | 143,259 | +200.6% | 0.03% | +160.0% |
| Q2 2023 | $3,890,323 | -85.6% | 47,658 | -86.9% | 0.01% | -87.0% |
| Q1 2023 | $26,987,725 | +651.9% | 363,765 | +740.0% | 0.08% | +600.0% |
| Q4 2022 | $3,589,201 | -80.4% | 43,306 | -32.7% | 0.01% | -82.3% |
| Q3 2022 | $18,266,000 | +132.1% | 64,318 | +183.3% | 0.06% | +138.5% |
| Q2 2022 | $7,869,000 | -18.7% | 22,702 | +21.3% | 0.03% | +23.8% |
| Q4 2021 | $9,680,000 | -33.2% | 18,710 | -37.4% | 0.02% | -34.4% |
| Q3 2021 | $14,488,000 | +287.6% | 29,900 | +260.2% | 0.03% | +300.0% |
| Q2 2021 | $3,738,000 | +878.5% | 8,300 | +730.0% | 0.01% | +700.0% |
| Q1 2021 | $382,000 | -82.5% | 1,000 | -88.6% | 0.00% | -85.7% |
| Q3 2020 | $2,182,000 | +77.8% | 8,810 | +89.6% | 0.01% | +16.7% |
| Q2 2020 | $1,227,000 | -1.9% | 4,647 | -22.6% | 0.01% | +50.0% |
| Q2 2019 | $1,251,000 | -44.8% | 6,000 | -61.7% | 0.00% | -55.6% |
| Q4 2018 | $2,267,000 | +162.7% | 15,664 | +119.5% | 0.01% | +200.0% |
| Q3 2017 | $863,000 | -66.0% | 7,135 | -67.0% | 0.00% | -66.7% |
| Q2 2017 | $2,539,000 | -70.3% | 21,610 | -72.3% | 0.01% | -71.0% |
| Q3 2016 | $8,549,000 | +165.1% | 78,070 | +173.0% | 0.03% | +121.4% |
| Q2 2016 | $3,225,000 | +186.2% | 28,599 | +139.9% | 0.01% | +180.0% |
| Q1 2016 | $1,127,000 | -45.2% | 11,919 | -46.5% | 0.01% | -54.5% |
| Q4 2014 | $2,057,000 | – | 22,263 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ownership Capital B.V. | 972,263 | $308,742,000 | 4.35% |
| Sandhill Capital Partners LLC | 138,864 | $44,096,000 | 4.03% |
| STONE RUN CAPITAL, LLC | 27,350 | $8,685,000 | 3.45% |
| DF DENT & CO INC | 925,823 | $293,995,000 | 3.42% |
| Brown Capital Management | 1,498,233 | $475,764,000 | 3.29% |
| MAIRS & POWER INC | 848,081 | $269,308,000 | 2.99% |
| Summit Creek Advisors LLC | 64,179 | $20,380,000 | 2.62% |
| GENEVA CAPITAL MANAGEMENT LLC | 402,958 | $127,959,000 | 2.17% |
| Aristotle Atlantic Partners, LLC | 86,993 | $27,625,000 | 2.13% |
| CROWN ADVISORS MANAGEMENT, INC. | 8,000 | $2,540,000 | 1.82% |